Luo Yushuang, Cui Sen, Tang Feng, Shen Cunfang, Qi Yujuan, Lu Dianxiang, Ma Lan, Yang Yingzhong, Li Yan, Chen Rong, Ri-Li G E
Research Center for High Altitude Medicine, Qinghai University, Medical School of Medicine, Xining, China / Department of Oncology, Affiliated Hospital of Qinghai University, Kunlong Road 16, Tongren Road 29, Xining, China.
Hematology Department, Affiliated Hospital of Qinghai University, Xining, China.
Pak J Pharm Sci. 2017 Sep;30(5):1629-1634.
This study aimed to investigate the efficacy of crocin alone and in combination with cisplatin in the therapy of gastric carcinoma cells. In this study, human gastric carcinoma cell line BGC-823 was purchased and maintained in standard condition. Crocin, cisplatin and crocin plus cisplatin diluted to different concentrations were added into medium, respectively. MTT assay and flow cytometry were performed to test the anti-proliferation effects and apoptosis rates of cells, respectively. In addition, quantitative RT-PCR was used to detect the mRNA expression of apoptosis-related genes, such as p53, Bax and Bcl-2. After treated with different concentrations of crocin, the inhibition ratio and apoptosis rate of BGC-823 cells were not significantly changed. However, the tumor cell inhibition ratio and apoptosis rate in crocin plus cisplatin group were significantly higher than that in cisplatin, crocin and control group (p<0.05). The treatment of crocin plus cisplatin significantly increased the expression of p53 and Bax (p< 0.05), and significantly decreased the Bcl-2 expression (p<0.05). Collectively, our data demonstrated for the first time that crocin plus cisplatin may be used as a new anticancer drug for the treatment of gastric cancer.
本研究旨在探讨西红花苷单独及联合顺铂治疗胃癌细胞的疗效。在本研究中，购买人胃癌细胞系BGC-823并在标准条件下进行培养。将稀释至不同浓度的西红花苷、顺铂及西红花苷加顺铂分别加入培养基中。分别采用MTT法和流式细胞术检测细胞的抗增殖作用和凋亡率。此外，运用定量RT-PCR检测p53, Bax和Bcl-2等凋亡相关基因的mRNA表达。用不同浓度的西红花苷处理后, BGC-823细胞的抑制率和凋亡率无明显变化。然而，西红花苷加顺铂组的肿瘤细胞抑制率和凋亡率显著高于顺铂组、西红花苷组和对照组(p<0.05)。西红花苷加顺铂处理显著增加了p53和Bax的表达(p<0.05)，并显著降低了Bcl-2的表达(p<0.05)。总体而言，我们的数据首次证明西红花苷加顺铂可作为一种新型抗癌药物用于治疗胃癌。
